Amylyx Pharmaceuticals, Inc
Financing
SEC filings to 2026-10-05 · every row opens its filingShares on issue
111.4M
on 2026-06-30, from 68.0M on 2024-03-31 10-Q ↗
a raise that quarter, at its price
Newest
No limit
S-3ASR of 2026-03-03. An automatic shelf: the form sets no dollar limit. 1 prospectus supplement filed under it since. S-3ASR ↗
1 of its filings are not read yet.
Warrants
The 10-Q filed 2026-08-06 is not read yet.
Cash
7.9 quarters
$250.8M on 2026-06-30 ÷ $31.6M a quarter of operating cash used, the average of four quarters. 10-Q ↗
| Date | What | Shares | Price | Gross | Filing |
|---|---|---|---|---|---|
| 2026-08-19 | Public offering | 14,090,000 | $35.50 | $500.2M | 424B5 ↗ |
| 2025-09-09 | Public offering | 17,500,000 | $10.00 | $175.0M | 424B5 ↗ |
| 2025-01-10 | Public offering | 17,142,857 | $3.50 | $60.0M | 424B5 ↗ |